Could a digital buddy system get people with diabetes moving?
NCT ID NCT07114822
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This trial tests whether online peer education can help people with type 2 diabetes become more physically active. Participants will be placed in groups led by peers who have type 2 diabetes and exercise above recommended levels. The study measures changes in daily step count, along with self-reported blood sugar and weight, over a 4-week period.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Harnessing Online Peer Education (HOPE) - a behavioral intervention where peer leaders with type 2 diabetes who exercise regularly engage participants in online groups to encourage more physical activity.
- What this could lead to
- If effective, this approach could offer a low-cost, scalable way to help people with type 2 diabetes increase physical activity and improve blood sugar control.
- What could go wrong
- This is a small, short-term trial (4 weeks) relying on self-reported data, so results may not be durable or generalizable. The intervention's success depends on participant engagement and peer leader effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years or older * Living in the US * Self-report diagnosis of type II diabetes * Has an app to track step count Exclusion Criteria: * On insulin or an injectable weight loss drug
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
UC Irvine
Irvine, California, 92617, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Effectiveness of shared decision Making(SDM)on patients with poor control type 2 diabetes
- A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin in patiEnts with non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM)
- Blood tests may reveal hidden healing power of bone marrow stem cells
- A Finger-Prick at the pharmacy could uncover silent diabetes
- Can a simple fish help tame type 2 diabetes?
- Can text messages help younger latinx adults tame type 2 diabetes?